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C/D-box snoRNAs form methylating and non-methylating 
ribonucleoprotein complexes: Old dogs show new tricks
Marina Falaleeva1, Justin R. Welden1, Marilyn J. Duncan2, and Stefan Stamm1,*
1University Kentucky, Institute for Biochemistry, Lexington, KY, USA
2University Kentucky, Department of Neuroscience, Lexington, KY, USA
Abstract
C/D box snoRNAs (SNORDs) are an abundantly expressed class of short, non-coding RNAs that 
have been long known to perform 2′-O-methylation of rRNAs. However, approximately half of 
human SNORDs have no predictable rRNA targets, and numerous SNORDs have been associated 
with diseases that show no defects in rRNAs, among them Prader-Willi syndrome, Duplication 
15q syndrome and cancer. This apparent discrepancy has been addressed by recent studies 
showing that SNORDs can act to regulate pre-mRNA alternative splicing, mRNA abundance, 
activate enzymes, and be processed into shorter ncRNAs resembling miRNAs and piRNAs. 
Furthermore, recent biochemical studies have shown that a given SNORD can form both 
methylating and non-methylating ribonucleoprotein complexes, providing an indication of the 
likely physical basis for such diverse new functions. Thus, SNORDs are more structurally and 
functionally diverse than previously thought, and their role in gene expression is under-
appreciated. The action of SNORDs in non-methylating complexes can be substituted with 
oligonucleotides, allowing devising therapies for diseases like Prader-Willi syndrome.
Keywords
alternative splicing; obesity; Prader-Willi syndrome; RNA methylation; RNA processing; RNA 
therapy; SNORD; snoRNA
The classic picture of snoRNAs
Small nucleolar RNAs are a highly expressed class of non-coding RNAs
Small nucleolar RNAs (snoRNAs) are an abundantly expressed class of non-coding RNAs 
(ncRNA) that accumulate in the nucleolus. They are about 60–300 nucleotides (nt) long and 
based on conserved sequence elements, snoRNAs are classified either as C/D box or H/ACA 
box. C/D box snoRNAs (SNORDs) contain C (RUGAUGA, R=purine) and D (CUGA) 
boxes, which are usually present in duplicates (C′ and D′ boxes) and up to two antisense 
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boxes hybridizing to the RNA target [1]. SNORDs are flanked by two termini that form a 
stem in the final SNORD ribonucleoprotein complex (SNORNP) (Figure 1A).
snoRNAs are highly expressed. For example, a typical mammalian cell contains an 
estimated 200,000 copies of SNORD3, and 20,000 copies of SNORD13/14 [2, 3], which 
compares to estimated 200,000 mRNA molecules in a cell [4]. snoRNAs are one of the 
longest and best studied ncRNAs, as their high expression allowed their sequencing using 
RNase-mapping in 1979 [5], shortly after Sanger sequencing became available [6].
Human SNORDs are located in introns and form ribonucleoprotein complexes through a 
multistep assembly process
Almost all of the currently known 267 human SNORDs are located in introns, with the 
exception of SNORD3@ (@ indicating all four human SNORD3 genes, see Box 1 for 
SNORD nomenclature), SNORD8, SNORD13, and SNORD118 (U8) that are controlled by 
their own promoters [7, 8]. The intronic localization connects SNORD biogenesis with the 
pre-mRNA processing of their hosting genes. After the splicing reaction, the introns are 
released as lariats, which are opened up by the debranching enzyme and are subsequently 
degraded through exonuclease where XRN1/2 acts on the 5′ end and the RNA exosome at 
the 3′ end [9, 10]. The close connection between pre-mRNA splicing and SNORD 
biogenesis is reflected by a distance requirement for SNORDs that are located around 33–40 
nt upstream of the branch point, which was shown using biochemical studies on a few 
SNORDs [11,12]. SNORDs escape degradation by associating with proteins in a snoRNP 
precursor, where the stem-termini forming a dsRNA stem that protects from exonucleases 
(Figure 1B). Proteomic studies deciphered the snoRNP assembly pathway for human U3 
snoRNA [13]. Central for the assembly is the R2TP complex (named after the yeast proteins 
ATPases Rvb1 and Rvb2 (named after E.Coli DNA repair enzyme ruvB), Pih1 (Protein 
interacting with Hsp90) and Tah1 (TPR-containing protein associated with Hsp90) [14]. 
TheR2TP complex acts like a chaperone allowing the formation of complexes between 
proteins and snoRNA.
The R2TP complex components RUVBL1 and RUVBL2 associate with the SNORD core 
proteins NHP2L1 (15.5k, SNU13) pre-bound to NUFIP and ZNHIT3, and NOP58 in an 
ATP-dependent manner, which releases PIH1D1 and RPAP3. This protein complex 
associates with the SNORD and fibrillarin, removing ZNHIT3. In a further maturation step, 
a second molecule of fibrillarin, as well as NOP56 enters the complex, removing the 
adaptors ZNHIT6 and NUFIP. Unloading of RuvBL1/2, leads to further rearrangement and 
generated the final snoRNP complex (Figure 1C). The components of this system are 
conserved from human to yeast, where it was shown that the R2TP components PIH1D1 and 
RPAP3 shuttle between cytosol and nucleus using the Crm1 and Kap121 export/import 
systems [15], which is regulated by the nutritional status of the cells via the mTOR pathway 
[15] (Figure 1D).
The described assembly pathway has been determined for SNORD3@, which are expressed 
under their own promoters, but given the similarity between snoRNP complexes, it is likely 
that intronic SNORDs follow a similar pathway. The knock-down of R2TP components in 
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yeast changes expression of several snoRNAs, suggesting that the general features of this 
pathway are conserved [16].
Intronic SNORDs use additional factors for maturation, for example, IBP160 (intron binding 
protein 160kd) that interacts with U2snRNP measures the distance between intron branch-
point, likely allowing for a folding of the SNORD [12]. Another factor is the spliceosome 
component Prp43p that is associated with SNORDs, possibly helping to recycle SNORDs 
during rRNA processing [17] and whose loss leads to extended SNORD ends upon deletion 
[18].
snoRNP structureThe SNORD-ribonucleoprotein complex positions the methylase 
fibrillarin towards the target RNA
The final snoRNP consists of two molecules NHP2L1 (15.5k, SNU13) bound to the RNA 
kink-turn formed by the C/D box interactions [19], one molecule of NOP56 and NOP58 
bridging these structures and two molecules of fibrillarin [13], reviewed in [20] (Figure 1E). 
Detailed insight into SNORD complexes came from cryo-EM and NMR based structural 
studies from archaeal SNORDs [21, 22], demonstrating that NHP2L1 (15.5k, SNU13) binds 
to the two RNA kinks formed by the interaction between the C and D and C′ and D′ boxes, 
forming a bipartite structure. These two domains are connected by NOP56 and NOP58, 
which is one molecule NOP5 in archaea. NOP5 stabilizes the binding of the methylase 
fibrillarin in this complex through direct interaction. The assembled SNORNPs form dimers, 
likely in a parallel orientation where the stems of the two monomers interact [22].
The SNORD RNA has two functions in this arrangement: first, it provides the scaffold for 
the RNP complex, by forming two RNA kink structures which locate 15.5/NHP2L1 and by 
forming a double stranded terminal stem that protects the RNA from further exonucleic 
cleavage. Secondly, two elements of the SNORD, known as antisense boxes are not covered 
with proteins and are thus free to interact with target RNAs. The antisense boxes recognize 
sequences in target RNAs resulting in the fifth nucleotide upstream of the D or D′ box 
being 2′-O-methylated by the methylase fibrillarin [1], which is properly positioned in the 
complex. The antisense boxes in eukaryotes vary in length (10–21 nt), but only a maximum 
of 10 nt can be used for modifications, due to the structure of the snoRNP [23]. With a few 
exceptions, such as the targeted U6 snRNA [24], SNORDs modify ribosomal RNAs at 
around 100 sites. Most of these modifications are constitutive and play a role in rRNA 
folding and translational fidelity [25]. However, some rRNA sites are only partially 
methylated and some SNORDS exhibit sequence complementarity to rRNAs without a 
resulting modification, which suggests additional functions for SNORDs [26,27]. A few 
SNORDs including SNORD3@ and U8 and U13 direct pre-rRNA cleavage [28]. In 
SNORD3@, the interaction with rRNA is mediated by SNORD3-specific sequences 
upstream of the C box [29].
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Diseases caused by snoRNA loss indicate new functions
orphan snoRNAsHalf of the known SNORDs are orphan, as they have no known target
The structure and targeting properties of SNORNPs allowed the identification of their likely 
targets through sequence comparisons using the known 2′-O-methylation sites of rRNA 
(Figure 1E). However, a target could be identified for only half of the known SNORDs. The 
remaining SNORDs were thus considered “orphan” [8, 30], suggesting that they might have 
other functions than 2′-O-methylation. The association of changes in SNORD expression 
with numerous diseases, where there were no obvious defects in ribosomal function, 
supports the concept that SNORDs mediate additional functions beyond rRNA methylation.
Loss of SNORD expression is critical for Prader-Willi syndrome (PWS)
Genetic defects in the 15q11.2-q13.1 regions provide some of the most striking examples of 
SNORDs functioning outside rRNA methylation. Due to imprinting, only the paternal allele 
of the 15q11.2-q13.1 region is expressed. Loss of the paternal allele, either through a 
deletion of the paternal allele or through uniparental disomy of the mother’s allele leads to 
Prader-Willi syndrome (PWS). PWS is one of the most frequent genetic causes of morbid 
obesity and intellectual disability in humans. It has a frequency of about 1:10,000–1:30,000 
individuals. In early infancy, PWS is characterized by severe hypotonia, which improves in 
later infancy and is followed by excessive eating (hyperphagia), leading to morbid obesity 
when untreated. PWS subjects further show low growth hormone levels, short stature, 
hypogonadism, a characteristic behavior with temper tantrums, manipulative behavior and 
obsessive-compulsive symptoms [31].
The imprinted region lost in PWS contains four protein-coding genes and six orphan 
SNORDs located in the 3′ UTR of the bicistronic SNURF-SNRPN gene. SNURF-SNRPN 
encodes the SNRPN protein, a member of the SmB protein family that forms spliceosomal 
snRNPs, and the nuclear SNURF (SNRPN upstream reading frame) protein of unknown 
function. The 3′ UTR of this transcript hosts six orphan SNORDs, each flanked by two non-
coding exons: SNORD107, -64, 108, -109a, -116 (29 copies falling into five distinct classes) 
and -115 (47 almost identical copies) (Figure 2A). The SNORDs are predominantly 
expressed in the brain, but can also be detected at lower levels in peripheral tissues [32]. The 
brain specificity increases towards 3′ end of the SNRPN-SNURF transcript and SNORD115 
can be detected only in neurons.
In addition to SNORDs, the Prader-Willi critical region generates five different snoRNA-
related IncRNAs (sno-IncRNAs) consisting of the introns surrounded by one copy of 
SNORD116 on both 5′- and 3′-end. The function and generation of these sno-lncRNAs 
remains to be determined [33].
Microdeletions affecting SNORD116 identified in six individuals recapitulate several 
features of PWS in a PWS-like phenotype that can be clinically hard to detect. Comparing 
all microdeletions identifies a region containing SNORD116 and SNORD 109, suggesting 
that the loss of these SNORDs plays a central role in PWS disease etiology [34–38] (Figure 
2A).
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The gene dosage of SNORDs in this region can not only be modified by deletion, but also 
doubled through duplications of the 15q11.2-q13.1 regions. Paternal interstitial duplications 
of 15q11.2-q13.1 double the SNORD gene doses, leading to Duplication 15q syndrome 
(Dup15q). Paternal duplications show variable penetrance for autism, in which they may be 
asymptomatic or associated with phenotypes ranging from anxiety and sleep disturbance 
[39] to developmental delay [40]. Similarly, mice overexpressing SNORD115 show autistic 
features [41], illustrating that SNORD expression levels must be under tight control to 
prevent disease.
The complex phenotypes associated with alterations in SNORD expression in the 15q11.2-
q13.1 region reveal the physiological importance of SNORDs and raise the question of their 
molecular function.
Changes of SNORD expression in many types of cancers
Changes in SNORD expression are also observed in several forms of cancer [42, 43]. For 
example, the chromosomal translocation breakpoint involved in some B-cell lymphomas is 
located in the non-protein coding gene SNHG5 (small nucleolar RNA host gene 5). SNHG5 
harbors SNORD50A which methylates C(2848) of 28S rRNA [44] and is lost in numerous 
breast and prostate cancer cell lines and primary tumors [45–47]. The ncRNA gene GAS5 
(growth arrest specific 5) regulates cell survival, possibly by sequestering glucocorticoid 
hormone receptors. GAS5 harbors 10 SNORDs, whose expression is highly associated with 
cancer prognosis [48–52] and SNORD78 from this cluster is a biomarker for lung cancer 
[53]. Similarly, the non-protein coding gene SNHG1 hosts SNORD-27, -25, -30, and -31 
(Figure 2B). Loss of these SNORDs mark the progression of smoldering multiple myeloma, 
which cannot be explained through their predicted roles in rRNA methylation [54]. It is 
known that the localization and function of the R2TP complex that is necessary to form 
snoRNPs (Figure 1B, D) is regulated by the mTOR pathway [15] and likely altered in cancer 
[14, 55], which could affect snoRNP formation, but the molecular role of these SNORDs in 
cancer cannot be explained by their action on rRNA.
Some SNORDs mediate Lipotoxic stress and influence cholesterol trafficking
Another unexpected role of SNORDs was unveiled in a screen aimed at identifying factors 
that mediate lipotoxicity, the physiological response to lipid overload in non-adipose tissues, 
which is caused by obesity. When non-adipose cells are stimulated by high lipid 
concentration, they activate a stress response that involves activation of NADPH oxidase, 
leading to mitochondrial dysfunction and finally cell death. Surprisingly, deletion of the 
SNORDs -32a, 33, 34, and 35a prevents this lipotoxicity [56]. These four SNORDs, rather 
than the ribosomal protein L13A (RPL13A) in which they are located, mediate the blockade 
of lipotoxcity. Unexpectedly, this study also found that three of these SNORDS accumulate 
in the cytosol after treatment with fatty acids [56]. A later study using RNAseq analysis 
found that 94/119 expressed SNORDs can be detected in the cytosol after drug-induced 
lipotoxcicty [57] and that the cytosolic accumulation of SNORDs is mediated by NADPH 
oxidases through an unknown mechanism [57]. As well as lipotoxicity, SNORDs participate 
in other processes, including glucose tolerance and cholesterol trafficking. Mice with a 
specific knock down of SNORD32A, 33, 34 and 35a that did not alter expression of the 
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protein encoded by the hosting genes RPL13A exhibited an increased systemic glucose 
tolerance and glucose-mediated insulin secretion [58]. Thus lack of these SNORDs 
promotes the clearance of circulating glucose possibly caused by decreased production of 
reactive oxygen species [58]. Using a similar screening system SNORD60 was found to act 
in intracellular cholesterol trafficking, which is independent of its suggested function in 
ribosomal RNA methylation [59]. SNORDs 32A, 33, 34, 35a and 60 are predicted to 
methylate ribosomal RNAs, but their role in lipotoxic stress and cholesterol trafficking, as 
well as their cytosolic function suggests additional functions. SNORD33 is also selectively 
increased in the serum of subjects with non-small cell lung carcinoma [60], but a possible 
link to lipotoxcicity remains to be determined. It is well established that reactive oxidative 
species activate mTOR signaling [61], which regulates the snoRNP assembly factors of the 
R2TP complex (Figure 1D), providing a mechanistic link between reactive oxidative species 
and snoRNP formation.
The expression of some SNORDs oscillates in circadian rhythm
Deep sequencing (RNA-seq) of Drosophila brains collected at multiple timepoints during 
the day and night identified transcripts that exhibit 24-hour profiles [62]. As well as 
identifying robust daily oscillations in a large number of genes, similar to previous 
microarray studies, this study revealed that ~10% of the cycling genes are ncRNAs including 
snoRNAs. SNORDs in seven dUhgs (drosophila U22 host genes) exhibited oscillations that 
peaked during the light phase and appeared to be driven by light [62]. The majority of the 
Uhgs SNORDs are predicted to target rRNAs, although some of them are orphan. Because 
not all SNORDs exhibited a daily rhythm, those that do may have specialized functions 
related to daily rest-activity rhythms. If so, such a function might echo the proposed role of 
alterations in SNORDS in human diseases with the alterations in daily rest-activity rhythms. 
For example, patients with Prader-Willi syndrome or Duplication 15q syndrome exhibit 
alterations in daily sleep-wake cycles and in sleep architecture [31, 39, 63].
SNORDs as biomarkers for diseases and physiological changes
A subset of SNORDs change their expression in aging in C. elegans, [64]. In humans, 
alteration of cardiac SNORD expression is associated with the tetralogy of Fallot, a frequent 
congenital malformation of the heart [65]. SNORDs could further be markers of diseases, as 
SNORD3A is the RNA most strongly overexpressed in blood of Creutzfeldt-Jacob patients, 
as well as in mouse models of prion disease [66]. SNORD33, SNORD66 and SNORD76 or 
their fragments can also be detected in blood, where they may serve as biomarkers for non-
small cell lung carcinoma [60]. The possible functionality of these SNORDs was tested in a 
proof of principle experiment, in which the addition of synthetic SNORD fragments to cell 
culture media led to an increase of several transcription factors and mRNAs involved in the 
innate immune response [67].
Similarly, SNORD126 is up-regulated in hepatocellular carcinoma and colorectal cancer and 
upregulates genes involved in the PI3-AKT pathway [68]. Osteoarthritis is the most common 
degenerative disease of the joints, characterized by joint cartilage breakdown that affects 
about 4% of the population. SNORD116 is up-regulated in posttraumatic osteoarthritis 
mouse models and horses with natural developed osteoarthritis, the latter show a four 
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hundred fold increase [69]. Smaller changes were observed for SNORD18, -49A, -58, -21, 
-27, -90 and 11.
Collectively, these reports suggest a role of SNORDs outside rRNA modification, as no 
defects in translation or general protein synthesis were associated with the diseases.
SNORDs form non-methylating ribonucleic protein complexes and are 
precursors for shorter RNAs
Understanding the role of SNORDs outside rRNA modification proved to be extremely 
difficult, predominantly because RNA targets cannot be bioinformatically predicted for most 
orphan SNORDs. Novel SNORD functions were indicated by genome wide RNA profiling 
of diseases that showed deregulation of numerous SNORDs, but gave little mechanistic 
insights [70–73] [65] [69]. A few SNORDs were analyzed in great detail using mostly 
transfection studies [74–76] and even transgenic mice [58, 77, 78], which gave insight in to 
physiological processes. Mechanistical insight has come from detailed biochemical analysis 
[79] and the development of new techniques identifying RNA:RNA interactions [80]. These 
diverse studies used human and mouse system and support the novel concept of SNORDs 
acting in non-methylating ribonucleic protein complexes, outlined here.
Since SnoRNA precursors contain complementary sequences, for example the future stems 
that inhibit degradation by exonucleases (Figure 1B). It is thus not surprising that some 
SNORDs are recognized by proteins binding to dsRNAs.
SNORD expressing units are precursors for miRNAs
miRNAs are generated from nuclear pri-miRNAs characterized by a stem-loop structure that 
is cut by the dsRNase drosha [81], leading to the export of a pre-miRNA into the cytosol, 
where it is further cleaved by dicer to 21 nt long miRNAs that are loaded onto argonaute 
proteins. The sequencing of RNAs associated with argonaute proteins that bind miRNAs 
revealed that several snoRNAs, both H/ACA and C/D box snoRNAs give rise to miRNAs 
[76, 82–85], previously reviewed in [70, 71]. Several studies showed a correlation between 
SNORD-derived miRNAs and diseases, for example cancer [55, 86]. Most of the studies rely 
solely on sequencing data, and thus the underlying biological mechanism and biological 
relevance of SNORD-derived miRNAs is unclear. However, several SNORD-derived 
miRNAs are associated with argonaute proteins, suggesting that they are functional in gene 
regulation [85].
SNORDs activate protein kinase R
The second dsRNA-binding protein identified to bind to SNORDs was protein kinase RNA-
activated (PKR). PKR contains a double strand RNA binding domain whose activation of 
viral dsRNAs is well established. However, lipotoxic stress caused by palmitic acid also 
activates PKR and unexpectedly, SNORDs and H/ACA snoRNAs were found associated 
with activated PKR, suggesting that under metabolic stress conditions SNORDs mediate a 
stress response to PKR [87]. SNORDs associated with PKR included SNORD50A and 50B 
that are lost in some forms of cancer [45, 46]. SNORD50A/B were also found to directly 
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bind to K-Ras, which decreases G-protein binding and subsequently the activity of K-ras 
[88]. The loss of SNORD50A/B expression is thus predicted to increase Ras-ERK1/ERK2 
signaling which could promote tumor formation. It is possible that in addition, PKR 
activation contributes to this process.
SNORDs can be precursors of piRNAs
SNORDs can also give rise to piRNAs, abundant 26–31 nt long non coding RNAs associated 
with PIWI proteins. The biogenesis of piRNAs is independent of DICER, and likely requires 
single stranded RNA [89]. One of these snoRNA-derived piRNAs, piR30840, works in 
nuclear-exosome mediated degradation of interleukin-4 pre-mRNA by recruitment of Ago4/
Piwil4 to an intronic site [90].
SNORDs form non-methylating ribonucleoprotein complexes
SNORD115 was the first SNORD shown to regulate alternative splicing [75] and thus 
proteins associated with SNORD115 were the first to be analyzed, using direct pull down 
from total nuclear lysates [74] as well as pull downs from nuclear extracts fractionated 
through a density gradient [91]. Both approaches indicated that SNORD115 associates with 
proteins different from the canonical SNORD proteins: 15.5/NHP2L1, NOP56, NOP58 and 
fibrillarin (Figure 1E). SNORD115 associated with hnRNPs (A1, B1, A3, D0, hnRNPL2, 
ELAVL1), RNA helicases (DHX9, DDX), structural proteins (nucleolin, matrin3), and 
transcription factors (PURA). The number of these proteins and the broad distribution of 
SNORD115 complexes in glycerol gradients [91] suggested the presence of structurally 
diverse SNORD115-protein complexes.
Further insight into the composition of new SNORD complexes came from the analysis of 
HeLa nuclear extract fractionated under native conditions [79]. In this method nuclei are 
extracted using native salt conditions, which preserve higher order structure, and the extracts 
are subsequently separated on native glycerol gradients. Surprisingly, 29 SNORDs were 
found in nuclear fractions associated with the spliceosome, representing about 24% of the 
expressed SNORDs. Although most of these SNORDs have been previously shown to 
methylate rRNA, the nuclear fraction containing these SNORDs was devoid of fibrillarin, 
NOP58 and NOP56. A detailed analysis of SNORD27, predicted to perform the known 2′-
O-methylation of A27 in 18S RNA [92], revealed that SNORD27 associated with diverse 
RNA binding proteins (FUBP3, FUBP1, KHSRP, hnRNPQ, L, ELAVL1,) and RNA 
helicases DDX5, as well as proteins implicated in splicing (PRPF3, PRPF4, SFPQ), which is 
reflected in the ability of SNORD27 to change splice site selection. The biochemical 
separation of SNORDs from fibrillarin-containing fractions was further confirmed using 
RNase protection for SNORD2, 60 and 78 [79].
SNORDs can be subdivided into two groups based on the number of paired nucleotides 
downstream of k-turn motif – one group has long ends (snoRNAL) and the other one short 
ends (snoRNASH) [8]. The processing of snoRNAL were more sensitive to NOP58 
depletion, in contrast the processing of snoRNASH was affected by depletion of splicing 
factor RBFOX2. This additionally suggests that there is more than one processing pathway 
for SNORDs that could lead to generation of diverse RNPs.
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Thus, the protein complexes formed by SNORD can be biochemically separated into 
complexes that contain fibrillarin (methylating SNORDs) and lacking fibrillarin (non-
methylating SNORDs). Together, these data suggest that SNORDs form protein complexes 
that lack the methylase fibrillarin, which we refer to as non-methylating SNORNPs in 
addition to the well-known methylating SNORNPs containing 15.5/NHP2L1, NOP58, 
NOP56 and fibrillarin. Some SNORDs, like SNORD27, 2, 60 and 78 form both complexes 
and thus have dual functions [79]. SNORD3@ is atypical, because it is not an intronic 
SNORD, but shows that methylating SNORDs do not necessarily perform 2′-O-methylation. 
SNROD3@ cleaves pre-rRNA using an extra 5′ sequence, containing A and B boxes that 
aid in rRNA cleavage site recognition. SNORD3@ also forms a classic methylating 
SNORNP that is used for nuclear localization, but not targeting [29].
Some SNORDs form shorter RNAs, processed snoRNAs (psnoRNAs)
Within the methylating SNORD-ribonucleoprotein particle, the RNA is protected from 
degradation by the associated proteins and a terminal stem. However, such a protection 
might not be the case in heterogenous and more loosely formed non-methylating SNORDs. 
Deep sequencing experiment showed the presence of SNORD fragments with a medium 
length longer than 27 nt, which distinguishes them from miRNAs having a length 
distribution of 21–22 nt [93, 94]. Using a cloning technique allowing the identification of 
SNORD-fragments detected by RNase protection analysis, the presence of SNORD 
fragments, termed psnoRNA for processed snoRNA was further confirmed for mouse 
SNORD115 and SNORD116 [73, 74]. The analysis of the human transcriptome using 
RNAseq showed the expression of psnoRNAs for the human 115, 116, 113, 114 families and 
SNORDs- 50, 19, 32B, 123, 111, 72, 93, 23 and 85 [72, 73], listed in Supplemental Figure 1.
Non–methylation snoRNPs could explain the presence of psnoRNAs, as not the whole 
SNORD RNA is protected in a well-folded non-methylating complex from the actions of 
RNases, but only shorter fragments are protected by RNA binding proteins. Inspection of the 
SNORDs known to generate psnoRNAs shows that with the exception of SNORD 115 none 
of these SNORDs has all four C, C′ D and D′ boxes in full consensus (Supplemental 
Figure 1), which could impair proper snoRNP folding.
What are the functions of non-methylating SNORDs?
The formation of non-methylating SNORDs can explain mechanistically the influence of 
SNORDs on gene expression, which could contribute to diseases caused by SNORD loss. 
As described above, due to the double-stranded nature of SNORD precursors, SNORDs can 
activate protein kinase R and SNORD fragments can become part of argonaute proteins, 
acting as miRNAs.
In addition, the function of SNORDs in non-methylating RNA:protein complexes is 
emerging. Glycerol gradient analysis shows a wide size distribution of non-methylating 
snoRNA-protein complexes [79,91], indicating their heterogeneity. The absence of the 
defined structures indicates that each part of the SNORD, not just the antisense boxes, is free 
to interact with other RNA molecules, which has been confirmed by detailed studies of 
SNORD:pre-mRNA interaction (Figure 2C–F).
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SNORDs bind to pre-mRNAs, regulating splice site selection
SNORD115 (previously called HBII-52) is an orphan SNORD expressed in the Prader-Willi 
critical region (Figure 2A). It shares an 18 nt sequence complementarity with the alternative 
exon Vb of the serotonin receptor 2C and promotes the inclusion of this exon [75] due to 
direct SNORD:mRNA interaction (Figure 2C). SHAPE assays showed that the serotonin 
receptor 2C pre-mRNA in this region forms a stable double stranded structure that 
sequesters the regulated splice site, causing exon skipping [95] (Figure 3A). A chemical 
screen identified pyrvinium pamoate as a substance that binds to this double-stranded region, 
changes the structure, which de-represses the regulated splice site [95]. Since SNORD115 
binds to the dsRNA structure, it likely acts through a similar structural change. The dsRNA 
of the serotonin receptor 2C pre-mRNA is stable enough to be A->I edited by ADAR2, 
which leads to exon activation by similarly disrupting the dsRNA area, which activates the 
regulated splice site [95,96]. SNORD115 has no influence of RNA editing, but changes the 
ratio between inclusion and skipping of a non-edited exon Vb into the serotonin receptor 
pre-mRNA through direct SNORD-pre-mRNA interaction.
Proof of principle experiments showed that SNORD115 can perform 2′-O-methylation of 
short artificial RNAs sent to the nucleolus by using reporter constructs driven by an RNA 
polymerase I promoter. SNORD115 can also influence editing of an RNA fragment 
corresponding to serotonin receptor 2C pre-mRNA when expressed under a RNA 
polymerase I promoter [97]. However, physiologically, the serotonin receptor 2C is 
controlled by a RNA polymerase II promotor and thus the endogenous transcripts are not 
associated with the nucleolus. SNORD115 knock out mice show a change in serotonin 
receptor 2C splicing, indicating that physiologically, SNORD115 changes splicing in the 
nucleoplasma [78].
SNORD27 has been known to methylate rRNA and the finding that it changes splice site 
selection similar to SNORD115 was thus surprising [79]. Bioinformatic prediction validated 
by mutational analysis showed that SNORD27 binds to the 5′ splice sites of the E2F7 
transcripts and most likely blocks U1 snRNP access, leading to exon skipping (Figure 2D). 
A similar effect was found for several exons that are only expressed in SNORD27’s absence, 
suggesting that repression of exons is a general function of SNORD27. Importantly, 
SNORD27 also regulates 2′-O-methylation of rRNA [44], indicating that the SNORD has a 
dual function in both rRNA modification, acting in a methylating snoRNP and in alternative 
splice site selection, acting in a non-methylating RNP [79].
A similar dual function has been reported for SNORD88C, which is predicted to guide 28S 
rRNA methylation [7], but also regulates the alternative splicing of the FGFR3 pre-mRNA 
[98], (binding sites indicated in Figure 2F).
SNORDs regulate gene expression by direct binding to RNA
A major impediment in understanding the interaction between non-methylating SNORDs 
and their target RNAs are the difficulties in determining the SNORD: target RNA 
interactions, as these interactions can occur across the whole SNORD molecule, not just the 
antisense boxes. Furthermore, RNA:RNA interactions are more promiscuous than 
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DNA:DNA interactions, allowing for example G:U base pairing and tolerating gaps. It is 
therefore not a surprise that the validation of bioinformatically predicted SNORD:pre-
mRNA interaction is poor. This problem has persisted now for over 20 years [99], preventing 
the understanding of orphan SNORD function. Recently, LiGation of interacting RNA and 
high-throughput sequencing (LiGR) was developed to detect RNA:RNA interaction [80]. In 
LiGR, RNAs are cross-linked with the psoralen derivative AMT (4′-Aminomethyl-
trioxsalen hydrochloride), a molecule selective for dsRNA, single stranded ends are trimmed 
with RNase R and the ligated RNAs sequenced. Using this method, an interaction between 
the orphan SNORD83B and three pre-mRNAs (NOP14, SRSF3 and RPS5) was detected. 
Knock-down of SNORD83B caused an increase of mRNA of these target genes, but not 
their pre-mRNA, suggesting that SNORD83B could regulate mRNA stability, (Figure 2E) 
[80]. Since the interaction between SNORD27 and E2F7 can be demonstrated by RNA pull 
down without crosslink [79] and was not detected using LiGR [80], it is likely that more 
SNORD-mRNA interaction exist.
A possible role of SNORDs in mRNA stability is also suggested by the overexpression of 
one copy of mouse SNORD116 in cells not expressing endogenous SNORD116, which 
changes the expression of about 200 mRNAs, but has no detectable influence on alternative 
splicing [100]. Thus, regulating mRNA stability, possibly similar to miRNAs [101] by 
competing with RNA stabilizing proteins, could be a more general function of non-
methylating SNORDs.
The comparison of these SNORDs acting in splice site selection and mRNA expression 
shows an emerging common mechanism: the SNORDs associate with various RNA binding 
proteins, likely forming diverse non-methylating snoRNPs. The sequence complementarity 
between target and SNORD RNA includes sequences outside the antisense boxes, which 
should be taken into account in any prediction programs (Figure 2F).
Substitution of non-methylating SNORDs to combat human disease
The concept that SNORDs act in non-methylating protein complexes suggested therapeutic 
approaches for diseases caused by SNORD loss. Whereas a methylating SNORD complex 
has to be assembled during the splicing reaction from a large intron through several 
assembly steps (Figure 1B,C), it might be possible to substitute a non-methylating SNORD 
using an oligonucleotide that recapitulates the SNORD-mRNA interaction. The use of 
RNase-resistant modified oligonucleotides makes them independent from the binding of 
protecting proteins. This concept was first tested to influence alternative splicing of the 
serotonin receptor 2C, recapitulating the effect of SNORD115, the first SNORD shown to 
regulate splice site selection [102, 103].
The serotonin receptor 2C regulates food intake
The serotonin receptor 2C (5HT2C) regulates food uptake through its action on pro-
opiomelanocortin (POMC) neurons in the hypothalamus. Activation of the 5HT2C receptor 
leads to an increase of phospholipase C, which activates c-fos leading to POMC synthesis in 
these neurons. Alpha-melanocyte stimulating hormone (alpha-MSH), which is generated by 
processing of the POMC precursor, activates neurons in the paraventricular nucleus (PVN) 
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via melanocortin 4 receptors [104,105]. Activation of PVN neurons induces satiety, i.e. 
cessation of eating (Figure 3E). Knock-out mice lacking the 5HT2C receptor thus exhibit 
hyperphagia and are obese [106], whereas activation of the 5HT2C receptor using an agonist 
such as the FDA approved drug, lorcaserin, inhibits food intake [107]. Since patients with 
Prader-Willi syndrome do not express SNORD115, they show a dysregulation of 5HT2C 
alternative splicing, as observed in mouse models of this syndrome [78].
The activity of the serotonin receptor 2C is regulated by its RNA processing
The 5HT2C pre-mRNA undergoes both pre-mRNA editing and splicing of its exon Vb, 
which generates at least 25 proteins that respond differently to serotonin binding [108, 109] 
(Figure 3C, D). Skipping of exon Vb generates RNA1 encoding a truncated receptor 
5HT2C_tr that is expressed as a protein [103]. The 5HT2C_tr is localized intracellularly 
and through heterodimerization sequesters the full-length receptor inside the cell [103,110], 
decreasing the receptor’s activity. Exon Vb inclusion generates RNA2. RNA2 formation is 
promoted by SNORD115 [75], resulting in a non-edited full-length receptor 
5HT2C_FL_INI, with the amino acids INI in the second intracellular loop. Editing through 
ADAR2 at five sites also promotes exon Vb inclusion, leading to 32 RNA2 isoforms. The 
editing changes three amino acids, leading to 23 full-length, edited receptors, 
5HT2C_FL_ed. The non-edited 5HT2C_FL_INI is constituitvely active and shows the 
strongest response to serotonin, whereas the edited isoforms show a weaker response to 
serotonin binding and their constitutive activity decreases with increased editing, with 
5HT2C_FL_VGV having no constitutive activity [109, 111, 112]. Mouse models indicate 
that loss of the full length non-edited 5HT2C isoform causes hyperphagia [113], most likely 
because of the weak serotonin response of the edited receptors.
Central to this system is a stable secondary structure containing the alterative exon Vb that 
dictates the processing of the RNA [95, 96]. The default processing is skipping of Vb: exon 
Vb can be activated by disrupting this structure, either by the editing of guanosine to 
inosines, leading to full-length edited receptors, or by binding of SNORD115, which likely 
opens the dsRNA structure, leading to the non-edited full-length receptor (Figure 3A).
The truncated RNA1-encoded protein is localized in the intracellular membrane systems, 
likely the endoplasmic reticulum and Golgi and sequesters the full-length RNA2-encoded 
receptor [110]. Without RNA1, the full-length receptor is localized at the plasma membrane 
and throughout the cell [114]. Due to the sequestration, RNA1-encoded receptors reduce the 
presence of the full-length RNA2 receptor at the surface (Figure 3E). Thus, the RNA1/
RNA2 isoform-ratio, which is controlled by SNORD115, regulates 5HT2C receptor activity 
by determining the surface concentration of the active receptor [110]. Because the 
SNORD115-5HT2C target interaction has been worked out (Figure 2C), efforts to find a 
substitution for SNORD115 concentrated on this system.
SNORD115 can be substituted with an oligonucleotide
Using an oligo-walk [115], an oligonucleotide, oligo#5 that strongly promotes exon Vb 
inclusion in cell culture [103], similar to SNORD115 was identified. Oligo#5 was then 
tested in vivo, by injecting it into the 3rd ventricle of wild-type C57/Bl6 mice. This treatment 
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with oligo#5 increased 5HT2C_FL_INI and decrease RNA1 in the hypothalamic arcuate 
nucleus, as expected, and importantly, robustly reduced food intake. Thus, SNORD115 can 
be functionally substituted using an oligonucleotide, which further shows that a methylase is 
not necessary for SNORD115 action. The data also indicate that the ratio between the two 
5HT2C proteins: a full-length receptor containing exon Vb and a truncated receptor lacking 
it, is involved in the regulation of food intake. Since it is known that the full-length receptor 
heterodimerizes with other transmembrane receptors [116, 117], it is possible that this ratio, 
controlled by the non-methylating SNORD115 contributes to the formation of the complex 
Prader-Willi syndrome by affecting different receptor systems.
Conclusion and outlook: snoRNAs can have multiple roles by forming 
different RNPs – a general role for ncRNAs?
The reviewed evidence shows that SNORDs have broader functions and more diverse 
properties than previously assumed. SNORDs not only form the well-studied methylating 
complexes, but in addition associate with hnRNPs and dsRNA binding proteins to form non-
methylating complexes. The compositional analysis of several non-methylating SNORD-
protein complexes showed a high degree of diversity, indicating multiple functions.
Similar to other processes in RNA biology, such pre-mRNA splicing, a balance between 
RNA elements adhering to consensus sequences, distance requirements and trans-acting 
protein factors likely dictates whether a SNORD forms a methylating or non-methylating 
ribonucleoprotein protein complex. A stronger divergence from the perfect consensus 
sequences likely favors non-methylating snoRNPs, which is reflected by the presence of 
psnoRNAs. For some SNORDs, the same SNORD expressing unit can form both 
methylating and non-methylating complexes, and this balance could be caused by 
modification of factors needed to form methylating snoRNA complexes.
Once a SNORD or its fragment becomes metabolically stable in a non-methylating SNORD 
complex it can acquire new functions by binding to other nucleic acids. As in the 
methylating snoRNP, the function of the RNA is twofold: it acts as a scaffold for the proteins 
and it binds to other nucleic acids via base-pairing. Studies of SNORD27 showed that its 
pre-mRNA targets are not evolutionary conserved, suggesting that SNORDs are acquiring 
new functions during evolution. Non-methylating SNORDs could also explain why some 
SNORDs accumulate in the cytosol under stress [56, 57]. For example, HuR/ELVAL1 was 
found bound to all non-methylating SNORD complexes analyzed so far. HuR/ELAVL1 
accumulates in the cytosol under oxidative stress condition [118] and thus could help 
transport associated non-methylating SNORDs out of the nucleus.
Due to the high expression of SNORDs –there are roughly as many SNORD3 transcripts as 
mRNA transcripts in a cell- SNORDs likely represent an important but underappreciated 
class of mRNA regulators.
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Abbreviations
ncRNA non-coding RNA
PKR protein kinase RNA
psnoRNA processed snoRNA
PWS Prader-Willi syndrome
SNORD C/D box snoRNA
snoRNA small nucleolar RNA
SNORNP SNORD ribonucleoprotein complex
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Box 1
Nomenclature of SNORDs
SNORDs have a confusing nomenclature, reflecting more than 30 years of research on 
these RNAs. The HUGO name is SNORD for small nucleolar RNA C/D box, followed 
by a unique number. Identical SNORDs made from different hosting genes are depicted 
with an @, such as SNORD3@. SNORDs in gene clusters have their position indicated, 
such as SNORD115-1. Historically, small nuclear RNAs were termed U for Uracil-rich, 
and given a number, such as U1, U2, U3, etc. Some of these small nuclear RNAs were 
later to be recognized as SNORDs, such as U3. Newly discovered snoRNAs were given 
consecutive numbers, which did not discriminate between C/D and H/ACA box 
snoRNAs. Sometimes these numbers have more meaning, for example U27 (now 
SNORD27) is predicted to guide methylation of A27 of the 18S rRNA. The numbers in 
SNORD and U names are usually the same, but there are exceptions, for example U8 is 
now SNORD118. Sequencing projects identified new SNORDs that were given names 
related to libraries, for example HBII-52, now SNORD115, was named after human brain 
library II, clone 52 and similarly MBII-52 stands for mouse brain library. Nomenclature 
questions can be best addressed by referring to the snoRNA database (www-
snorna.biotoul.fr) or the genecard database (http://www.genecards.org).
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Figure 1. 
Structure and formation of methylating snoRNP complexes. A: General structure of C/D box 
snoRNAs (SNORDs) Overall structure of a C/D box snoRNA. C, D: C and D boxes, with 
consensus sites indicated. Yellow circles indicate the stem termini, short regions that are 
complementary to each other. M: middle box, defined in some SNORDs acting in pre-
mRNA processing, AS: antisense box. B: Excision of intronic SNORDs. The SNORD (thick 
line flanked by circles depicting the termini) is located in an intron ≈33–40 nt upstream the 
branch point (bp). Boxes indicate the flanking exons. In the lariat the sequence between the 
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branchpoint and the SNORD is occupied by IBP160, which likely facilitates in folding the 
SNORD. The lariat structure is opened through the debranching enzyme and then degraded 
by exonucleases (red half circles). This RNA structure forms the SNORDRNP complex by 
interacting with proteins assembled by the R2TP complex. C: Formation of the snoRNP. 
Proteins associated with the mature snoRNP are shown in pink, the R2TP components 
RuvBL1/2 in gray and auxiliary factors in orange. The R2TP complex assembles with a 
preformed 15.5/NUFIP/ZNHIT3 complex, and NOP58 and ZHHIT6, which requires ATP 
bound to RuvBL1/2. This protein complex binds to the nascent snoRNA in a step that 
incorporates fibrillarin (Fib) and releases ZNHIT3. The snoRNP further matures due to the 
addition of the second fibrillarin molecule and NOP56, releasing ZHHIT6 and NUFIP. The 
RUVBL1/L2 complex catalyzes the final structural arrangements and is recycled as the 
R2TP complex after release of the mature snoRNA. Note that this pathway has been worked 
out for SNORD3@, which is not an intronic RNA, but one regulated by its own promoter 
and due to the sequence conservation, it is likely that intronic SNORDs follow the same 
maturation pathway. D: The activity and intracellular localization of the R2TP complex is 
regulated by the mTOR pathway sensing nutritional status and possibly other phosphatidyl 
inositol 3′ kinase-related kinases (PIKK), which was shown in yeast. E: Structure of a 
methylating SNORNP. The SNORD forms a protein complex made of 15.5 (also known as 
SNU13 and NHP2L1), NOP56/58 and the methylase fibrillarin (Fib) that 2′-O-methylates 
(H3CO-) rRNA at a defined position (5 nt upstream of the D box). The coloring of the 
SNORD is similar to Figure 1A. Circles indicate the base interaction within the RNA kink. 
Only one antisense box is shown in rRNA targeting, but both antisense boxes can be used. 
The structure is adopted from an archea snoRNP, based on NMR and cryo-EM studies [21, 
22]. In the diagram, we used a shorter stem, which is 2–5 nt in humans [8, 119] and 
substituted the archea single NOP5 protein with the human NOP56 and NOP58 proteins.
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Figure 2. 
SNORDs involved in human disease and their function outside rRNA methylation. A: 
Schematic structure of Prader-Willi syndrome critical region (PWSCR). Genes are ovals, 
SNORDs are gray lines. Each SNORD is surrounded by two non-coding exons as shown in 
the insert above. IC: imprinting center, BP: breakpoint, cen: centromer, tel: telomer The 
microdeletions identified in four patients leading to a PWS-like phenotype [34–37] are 
indicated. B: Schematic structure of the SNHG1 (small nucleolar RNA host gene 1) 
harboring SNORD27, -25, -30, and -31 marking the progression of smoldering multiple 
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myeloma. SNHG1 is a non-protein coding gene, consisting of exon (boxes) that flank the 
SNORDs (gray lines). C: Binding of SNORD115 to the alternative exon Vb of the serotonin 
receptor 2C, identified by bioinformatic prediction [32] and validated by mutation analysis 
[75]. The D box is highlighted. D: Binding of SNORD27 to the alternative exon in the E2F7 
pre-mRNA, experimentally validated through mutagenesis [79]. C and D boxes are shown, 
as well as the binding of the methylating snoRNP to 18S rRNA, leading to the modification 
of A27. Small letters indicate the intron. E: Interaction between SNORD83B three mRNA 
targets which regulates their expression levels as determined by LiGR [80]. F: Scheme of 
interactions between SNORDs and pre-mRNA targets. The schematic structure of a SNORD 
is shown and the site of interaction with various pre-mRNA and mRNAs indicated by lines. 
Note that the sites of interaction include the C and D boxes.
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Figure 3. 
Substituting SNORD115 with an oligonucleotide. A: Secondary structure of the serotonin 
receptor 2C pre-mRNA that encompasses exon Vb between the proximal (PS) and distal 
(DS) splice sites (yellow). Intron V is shown in small letters. In this structure, the distal 
splice site is blocked and the proximal site used. Binding of SNORD115 to the boxed site 
likely causes a structural change, similar to binding of pyrvinium pamoate [95], which 
activates the distal site. Editing of up to four adenosines (red boxes) to guanosines similarly 
activates the distal splice site by weakening the RNA stem. Oligo#5 complementary to the 
green region strongly activates the distal site [103]. B: Gene structure of the 5HT2C. Exons 
are shown as boxes and the alternative splice patterns indicated by dashed lines. The region 
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in (A) is indicated by a yellow box and the location of oligo#5 is shown. The start codon in 
exon III is indicated by a round arrow. Skipping of exon Vb results in an early stop codon 
(open square arrow), whereas its inclusion results in a later stop codon (black square arrow). 
C: RNA isoforms generated by the processing events. Exon Vb skipping generates RNA1 
and its inclusion generates RNA2. Due to editing combinations, RNA2 represents 32 RNA 
isoforms. SNORD115 and oligo#5 promote the inclusion of the non-edited exon Vb. D: 
Protein isoforms generated by the processing events. RNA2 encodes 24 isoforms, one non-
edited isoform 5HT2C_FL_INI with the amino acids INI in the second intracellular loop and 
23 isoforms (5HT2C_FL_ed) that are edited. Circles in the second intracellular loop of the 
serotonin receptor 2C indicated non-edited amino acids and stars depict the editing events. 
E: Effect of the isoform ratios in on signaling POMC-neurons. Left: 5HT2C_tr is present in 
intracellular membranes (ER/golgi) and sequesters the full-length receptor, stopping its 
signaling at the plasma membrane (PM). The lack to signaling does no inhibit food intake, 
such generating an orexic response. Right: A relative decrease of 5HT2C_tr caused by 
SNORD115 or oligo#5 leads to an increased occupation the full-length receptors at the 
plasma membrane surface and its signaling via the phospho lipase C (PLC) pathway. PLC 
activation induces c-fos, which activates POMC transcription. The resulting POMC peptide 
is processed into alpha Melanocyte-stimulating hormone (αMSH), which activates 
Melanocortin 4 receptors (MCR4) receptors in the paraventricular nucleus, which results in 
an anorexic behavior response.
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Figure 4. 
SNORDs generate methylating and non-methylating complexes. It is likely that there are 
differences in processing between individual SNORDs and this scheme summarizes general 
features. A: Generation of snoRNAs: Almost all human SNORDs are intronic and are 
released from their hosting genes through pre-mRNA splicing, debranching of the lariat and 
exonucleic trimming. The location of a SNORD flanked by terminal stems in a hosting 
intron is shown; the boxes depict exons. The released RNA forms different ribonucleic 
protein (RNP) complexes: Methylating snoRNPs and non-methylating snoRNPs. B: 
Methylating SNORDs are generated using the R2TP system (RUVBL1/2) [20], which is 
regulated by mTOR pathways. Methylating SNORDs perform 2′-O-methylation of rRNA in 
the nucleolus. In addition, SNORD3@, containing the methylase fibrillarin (fib) acts in 
rRNA cleavage. The structure of a methylating SNORNP, consisting of a terminal stem, two 
kinks formed by C and D boxes are shown. The SNORD binds to the target rRNA via its 
antisense boxes and performs 2′-O-methylation at a specific rRNA ribose, 5 nt downstream 
of the D box. C: Non-methylating SNORDs are generated through the association of 
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SNORDs with diverse proteins, either dsRNA binding proteins (blue, PKR: protein kinase 
R, drosha) or hnRNPs and other RNA binding proteins (grey circles, ovals). SNORDs 
activate PKR and can be processed by drosha similar to miRNAs, leading to their 
incorporation in to argonaute proteins (ago). SNORDs stabilized by hnRNPs bind directly to 
pre-mRNA via RNA-RNA interaction and change pre-mRNA alternative splicing [74] and 
mRNA expression [80], likely through changing the stability of the mRNA. Some of the 
SNORDs in non-methylating RNPs are further processed into psnoRNAs [70], possibly 
protected by hnRNPs from further degradation. The association of non-methylating 
SNORDs with shuttling proteins, such as HuR could explain their detection in the cytosol, 
which is promoted by NADPH superoxidase function [57].
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